A novel liposomal adjuvant system, CAF01, promotes long-lived
2014年12月12日 · CAF01 is a novel two-component liposomal adjuvant system composed of a cationic liposome vehicle (dimethyldioctadecyl-ammonium (DDA)) stabilized with a glycolipid …
用于结核病疫苗的脂质体递送系统/佐剂 - 搜狐
2024年8月3日 · caf01（脂质体中的tdb）已被强调对结核病和hiv的细胞和体液反应具有强大的佐剂效果。 在接种的小鼠中，DMT能够诱导抗原特异性的CD8+ T细胞反应。 此外，与BCG组相 …
CAF01® | Croda 禾大医药健康 - crodapharma.cn
CAF01是Statens Serum Institut (SSI)1开发的全合成脂质佐剂系统，由阳离子季铵盐DDA和糖脂TDB2组成。 CAF01能够提高Th1和Th17的免疫应答，因此具有长期保护和免疫记忆功能。 …
Development and Evaluation of CAF01 - ScienceDirect
2017年1月1日 · The CAF01 doses were in rats up to six times and in rabbits up to four times as high as the anticipated human dose of 625/125 μg DDA/TDB, thereby maximizing exposure to …
The cationic liposomal adjuvants CAF01 and CAF09
2017年3月23日 · CAF01 contains the immune stimulating synthetic glycolipic trehalose-dibehenate (TDB) incorporated into cationic dimethyldioctadecylammonium bromide (DDA) …
CAF01® - Croda Pharma
CAF01 is a fully synthetic liposome-based adjuvant system developed by Statens Serum Institut (SSI.) It is comprised of DDA, a cationic quaternary ammonium salt, and the glycolipid TDB. …
疫苗前沿 | 结核病蛋白亚单位疫苗佐剂研究进展医药新闻-ByDrug
2024年11月27日 · caf01是一种基于该佐剂和tdb组成的双组分脂质体佐剂，该佐剂在注射部位显示出持久的储存效应，并能够诱导产生强烈的体液和细胞免疫应答 [92] 。 基于CAF01制备的多 …
A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8
2009年9月11日 · We tested the ability of a novel two component adjuvant, CAF01, consisting of the immune stimulating synthetic glycolipid TDB (Trehalose-Dibehenate) incorporated into …
CAF01 also induced a Th17 response due to TDB signaling through the C-type lectin receptor Mincle [14]. CAF01 adjuvanted H1 vac-cine was protective in animal models of TB [11–13,15], …
A novel liposomal adjuvant system, CAF01, promotes long-lived ... - PubMed
2014年12月12日 · Here, we report on a first-in-man trial where the tuberculosis (TB) vaccine Ag85B-ESAT-6 (H1) was adjuvanted with escalating doses of a novel liposome adjuvant …